Charles River Laboratories International, Inc.
CRL
$155.46
$2.801.83%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.02B | 4.02B | 4.03B | 4.02B | 4.05B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.02B | 4.02B | 4.03B | 4.02B | 4.05B |
| Cost of Revenue | 2.61B | 2.63B | 2.62B | 2.63B | 2.64B |
| Gross Profit | 1.40B | 1.40B | 1.41B | 1.40B | 1.41B |
| SG&A Expenses | 727.81M | 729.02M | 742.69M | 722.72M | 723.62M |
| Depreciation & Amortization | 174.87M | 124.08M | 129.07M | 132.16M | 127.87M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.51B | 3.48B | 3.49B | 3.48B | 3.49B |
| Operating Income | 501.96M | 542.35M | 539.32M | 540.39M | 556.46M |
| Income Before Tax | -99.50M | -22.20M | -18.15M | 30.08M | 93.11M |
| Income Tax Expenses | 42.66M | 57.43M | 46.73M | 53.39M | 67.82M |
| Earnings from Continuing Operations | -142.16 | -79.62 | -64.88 | -23.31 | 25.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.18M | -2.66M | -2.16M | -1.98M | -3.09M |
| Net Income | -144.34M | -82.28M | -67.04M | -25.29M | 22.20M |
| EBIT | 501.96M | 542.35M | 539.32M | 540.39M | 556.46M |
| EBITDA | 880.77M | 861.39M | 932.39M | 864.54M | 881.10M |
| EPS Basic | -2.95 | -1.55 | -1.31 | -0.63 | 0.17 |
| Normalized Basic EPS | 4.73 | 4.78 | 4.95 | 4.84 | 5.14 |
| EPS Diluted | -2.96 | -1.56 | -1.33 | -0.65 | 0.15 |
| Normalized Diluted EPS | 4.71 | 4.77 | 4.93 | 4.82 | 5.11 |
| Average Basic Shares Outstanding | 198.26M | 200.18M | 202.36M | 204.76M | 205.52M |
| Average Diluted Shares Outstanding | 198.81M | 200.73M | 202.89M | 205.42M | 206.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |